ClinicalTrials.gg
CompletedNCT04485546DEFENDOUpdated Nov 17, 2025Results posted

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

A Phase 4 interventional study of cenegermin-bkbj in Neurotrophic Keratitis, sponsored by Dompé Farmaceutici S.p.A. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Dompé Farmaceutici S.p.A · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Corneal Diseases with a site in United States — 12 open to participants now, 13 under way, 3 of them phase 3. Corneal Diseases · United States.

Enrollment
36th of 54
37 · median 79
Started
2020
with 1 other
Phase 4
5 of 76
none open now
Registered
54th of 76
by date

Among the 76 studies in Corneal Diseases with a site in United States, this one is the 36th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 4, and was the 54th registered.

Corneal Diseases

219 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.

Browse Corneal Diseases studies →

Open to participants now

12 of the 76 studies in Corneal Diseases with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Corneal Diseases studies recruiting now, 21 (64%) set no upper age limit and 5 (15%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Corneal Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).

Read the detailed description

This is a 8-week, multicenter, open label, prospective study with 24 weeks of follow-up to evaluate safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK)

03

Conditions studied

  • Neurotrophic Keratitis

Browse trials for

Keywords

  • Stage 1 Neurotrophic Keratitis
  • Corneal Disease
  • Ocular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥ 18 years.
  2. Patients with Stage 1 NK defined by the Mackie criteria

Exclusion criteria

Exclusion Criteria:

  1. Evidence of an active ocular infection (bacterial, viral, protozoal) in either eye.
  2. Have current or history of conditions that may confound the study data including but not limited to Ocular Cicatricial Pemphigoid (OCP), (GVHD), neuromyelitis optica, uncontrolled dry eye, and Steven Johnson's syndrome.
  3. History of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis expected during the subject's participation in the trial) or chronic conjunctivitis and/or keratitis other than dry eye disease.
  4. Patients with severe vision loss with no potential for visual improvement in the study eye, in the opinion of the investigator, or if the subject is deemed legally blind.
  5. Ocular surgery or elective ocular surgery expected during participation in the trial.
  6. Patients with eyelid abnormality that may alter eyelid function including but not limited to Blepharospasm, Cerebrovascular accident, entropion, ectropion, floppy lid syndrome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj

    cenegermin-bkbj ophtalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks

    Drug: cenegermin-bkbj

Interventions

  • OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered as one drop in the affected eye(s), 6 times a day at 2-hour intervals for 8 weeks, in patients with Stage 1 neurotrophic keratitis.

    Also known as: OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution

06

What researchers measure

Primary outcomes

  1. Corneal Epithelial Healing

    Percentage of patients who experienced corneal epithelial healing. Corneal epithelial healing was defined by the central reading center as the absence of persistent epithelial staining abnormalities related to disease.

    Time frame: Week 8

07

Results

Posted Jun 23, 2023

Participant flow

Participant flow — Overall Study
MilestoneOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
Started37
Completed29
Not completed8

Outcome measures

PrimaryCorneal Epithelial Healing

Percentage of patients who experienced corneal epithelial healing. Corneal epithelial healing was defined by the central reading center as the absence of persistent epithelial staining abnormalities related to disease.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Corneal Epithelial Healing
ParticipantsOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
No5
Yes28

Adverse events

Collected over 34 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Study Eye0/37 (0%)1/37 (2.7%)22/37 (59.5%)
OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Non Study Eye0/37 (0%)0/37 (0%)13/37 (35.1%)
OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Systemic1/37 (2.7%)7/37 (18.9%)16/37 (43.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Study EyeOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Non Study EyeOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Systemic
Myocardial infarctionCardiac disorders0/370/371/37
COVID-19Infections and infestations0/370/371/37
SyncopeNervous system disorders0/370/371/37
Hiatus HerniaGastrointestinal disorders0/370/371/37
Incarcerated parastomal herniaInjury, poisoning and procedural complications0/370/371/37
Pneumonia bacterialInfections and infestations0/370/371/37
Deep Vein ThrombosisVascular disorders0/370/371/37
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/370/371/37
IridocyclitisEye disorders1/370/370/37
Intestinal HaemorrhageGastrointestinal disorders0/370/371/37
Most frequent other events
Showing 10 of 61
Most frequent other events
EventOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Study EyeOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Non Study EyeOXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Systemic
Eye PainEye disorders14/372/370/37
Vision blurredEye disorders7/373/370/37
Dry EyeEye disorders4/372/370/37
Foreign body sensation in eyesEye disorders4/370/370/37
Eye irritationEye disorders3/372/370/37
Eyelid painEye disorders3/372/370/37
Burning sensationNervous system disorders3/371/370/37
Corneal DystrophyCongenital, familial and genetic disorders2/371/370/37
Conjunctival hyperaemiaEye disorders2/371/370/37
Corneal OedemaEye disorders2/371/370/37

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
<=18 years0
Between 18 and 65 years19
>=65 years18
Age, Continuous
Age, Continuous(years)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
Mean64.6 ± 11.89
Sex: Female, Male
Sex: Female, Male(Participants)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
Female28
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
Hispanic or Latino2
Not Hispanic or Latino35
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
Race — White32
Race — Black or African American3
Race — Asian1
Race — Other1
Region of Enrollment
Region of Enrollment(participants)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
United States37
Treated Eyes
Treated Eyes(participants)OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj
Participants with Treated Study Eye37
Participants with Treated Non-Study Eye15
08

Study locations

5 sites
  • San Diego
    San Diego, California 92122, United States
  • Edgewood
    Edgewood, Kentucky 41017, United States
  • Boston
    Boston, Massachusetts 02111, United States
  • Saint Louis
    St Louis, Missouri 63131, United States
  • Philadelphia
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal Nerves. J Cell Physiol. 2017 Apr;232(4):717-724. doi: 10.1002/jcp.25623. Epub 2016 Oct 17. PubMed 27683068 ↗
  • Hamrah P, Massaro-Giordano M, Schanzlin D, Holland E, Berdy G, Goisis G, Pasedis G, Mantelli F. Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO). Ophthalmol Ther. 2024 Feb;13(2):553-570. doi: 10.1007/s40123-023-00866-y. Epub 2024 Jan 4. PubMed 38175466 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Sep 2021, 12 months.

Results were first posted in Jun 2023, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2020
First posted
Jul 24, 2020
StartActual
Sep 9, 2020
Primary completionActual
Sep 30, 2021
CompletionActual
Mar 30, 2022
Results first posted
Jun 23, 2023
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04485546
Collaborators
Dompé, US, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Sep 9, 2020
Primary completion
Sep 30, 2021
Completion
Mar 30, 2022
Results posted
Jun 23, 2023
Last update
Nov 17, 2025

Study contacts

Flavio Mantelli, MD, PhD
study chair · Domp Farmaceutici SpA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenegermin

Start the discussion